New Research Links GLP-1 Medications to Potential Cancer Benefits
GLP-1 medications, traditionally used for treating diabetes and obesity, may also help in reducing cancer risk and improving survival rates, according to new insights.
Dr. Loren Rourke, a breast cancer surgeon from Texas, pointed out that growing evidence suggests drugs like Ozempic and Wegovy might lower the chances of developing certain cancers, including breast cancer. Recent findings presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago highlighted a connection between GLP-1 usage and reduced recurrence rates of breast cancer.
Despite this encouraging news, Dr. Rourke cautioned that these findings are based on observational studies and cannot definitively prove that GLP-1 medications prevent cancer. “Patients shouldn’t rush to their doctors to request these treatments solely for cancer prevention,” she said. However, the research does spotlight a potential beneficial link worth exploring further.
Understanding the Connection
The reason GLP-1 medications could aid in cancer prevention lies in their ability to promote weight loss and decrease chronic inflammation. Dr. Rourke explained that lower body mass index (BMI) often leads to better outcomes for breast cancer patients. “If using a GLP-1 helps with weight loss, that can be a significant advantage,” she noted.
Moreover, these medications can also lower estrogen levels associated with excess body fat, which is important since a higher fat percentage can lead to increased estrogen production in the body. “Being overweight can lead to a situation where your body is flooded with estrogen, which isn’t ideal,” Dr. Rourke observed.
GLP-1s also help combat the chronic inflammation that can contribute to cancer development. “Reducing this inflammation can have various health benefits,” she added.
Call for More Research
While the connection appears promising, further research is necessary to determine if GLP-1 medications directly affect cancer cells. “Currently, we lack solid proof linking these drugs directly to breast cancer cell behavior,” Dr. Rourke stated.
She emphasized the importance of investing in more rigorous studies, including randomized controlled trials, to better understand the potential links between GLP-1 medications and cancer outcomes.
For patients considering GLP-1 treatments, Dr. Rourke recommends consulting healthcare providers, especially if they’re struggling with weight management despite efforts like diet and exercise. She particularly highlighted the potential benefits for post-menopausal women.
In summary, while GLP-1 medications show promise for weight loss and potentially lowering cancer risks, ongoing research is essential to confirm these findings.
